Studies on Cardiovascular Disease in the Cat*

Tashjian, Robert J.; Das, Krushna M.; Palich, William E.; Hamlin, Robert L.; Yarns, D. A.

doi:10.1111/j.1749-6632.1965.tb49425.x

Cited by 18 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, neither PIMO nor benazepril showed any tendency toward a change in echocardiography measurements or GFR during the study, making it unlikely that these caused the myxomatous mitral valve degeneration. In an early study of the incidence of cardiovascular disease in cats, of the 202 cats examined at necropsy, 12 (5.9%) had mitral valve lesions (including endocarditis, fibrosis and stenosis) and 17 (8.4%) had myocardial lesions (including hypertrophy, hemorrhage, infarct and fibrosis) [ 20 ]. In our cats, the prevalence of mitral valve degeneration was much higher, but no cat had clinical evidence of mitral regurgitation during the study period.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the effects of long-term pimobendan and benazepril administration in normal cats

Miyagawa

Motomura

Toda

et al. 2016

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

Pimobendan (PIMO) can cause adverse effects, such as mitral valve degeneration, in dogs; however, it is unclear whether these effects occur in cats. Therefore, we aimed to determine whether PIMO or benazepril produces adverse cardiac effects in healthy cats. This was a blinded, randomized, prospective parallel study. Twelve cats were randomly divided into two groups of six cats, namely, an angiotensin-converting-enzyme inhibitor group that received benazepril and a PIMO group. Cats were administered their respective treatments for 506 days, and we evaluated cardiac parameters, blood biochemistry and glomerular filtration rates during that time. At the end of the trial, the cats were euthanized, and histopathological examinations were performed by a pathologist who was blinded to the treatment groups. No significant changes were observed in any of the parameters measured in either of the groups. In particular, no significant cardiac lesions were observed in either of the groups. In healthy cats, neither PIMO nor benazepril appears to cause cardiac lesions, but future studies are needed to examine the effects of PIMO in cats with heart disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the effects of long-term pimobendan and benazepril administration in normal cats

Miyagawa

Motomura

Toda

et al. 2016

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

show abstract

“…Angiotensin receptor blockers (ARBs) inhibit type I angiotensin II (AT1) receptor distributed in blood vessels and heart, and thus exert similar pharmacological action of ACEI. Because the ARBs only block type I receptor, they can reduce risk of renal injury from full inhibition of ACE [114]. Therefore, it can use for treating dogs with CHF, when the ACEIs cause renal azotemia [115].…”

Section: New Therapeutic Agents In Dogs With CMVImentioning

confidence: 99%

Chronic Mitral Valve Insufficiency in Dogs: Recent Advances in Diagnosis and Treatment

Suh¹,

Han²,

Lee³

et al. 2016

Canine Medicine - Recent Topics and Advanced Research

View full text Add to dashboard Cite

Chronic mitral valvular insufficiency (CMVI) is the most common acquired heart disease in dogs and is characterized by degenerative valvular changes causing progressive thickening of mitral leaflets and incomplete closure of mitral valve. As the disease progresses, it causes congestive heart failure (CHF) and pulmonary edema if the LA dilation cannot accommodate the volume overload by mitral regurgitation. Therefore, it is the most common cause of cardiac mortality in dogs. This chapter discusses general features of CMVI in dogs focusing on recent advances in diagnosis and treatment.

show abstract